Aptose Biosciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Aptose Biosciences is set to be acquired by Hanmi Pharmaceutical for C$2.41 per share, providing a definitive path forward for the company despite ongoing financial challenges and promising clinical results for its lead oncology asset, tuspetinib.
Aptose Biosciences Inc. files its 2024 10-K, highlighting clinical advancements in tuspetinib and luxeptinib programs while addressing financial challenges and Nasdaq compliance.
Aptose Biosciences Inc. filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and corporate governance.
Aptose Biosciences Inc. released its annual 10-K filing, detailing financial results and progress in clinical trials for its lead drug candidates, tuspetinib and luxeptinib.